This further confirmed the critical role of inflammatory pathways acquired from network pharmacology, particularly the TLR4/NF-κB/COX-2 pathway, in the molecular mechanism of WSF on NAFLD treatment. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.